PerkinElmer has introduced a dry blood spot-based serology test for SARS-CoV-2 immunoglobulin G (IgG) antibodies using its genetic screening processor (GSP)/dissociation-enhanced lanthanide fluorescence immunoassay (DELFIA) platforms.
Up to 5,000 samples of the fully automated kit can be processed per day, according to the company. PerkinElmer said that the finger-prick sample collection devices enable both decentralized sample collection and high-throughput testing.
In Europe, the kit is being marketed as a CE-IVD test. The firm plans to apply for an emergency use authorization with the U.S. Food and Drug Administration.